TrialBritish journal of clinical pharmacology2013

Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.

Linda E Klumpers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.